Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Int J Gynecol Cancer. 2020 Aug;30(8):1195-1202. doi: 10.1136/ijgc-2020-001243. Epub 2020 Jul 2.
In the United States, trends in the initial treatment approach for ovarian cancer reflect a shift in paradigm toward the increased use of neoadjuvant chemotherapy and interval cytoreductive surgery. The aim of this study was to evaluate the trends in surgical cytoreductive procedures in ovarian cancer patients who underwent either primary or interval cytoreductive surgery.
This retrospective, population-based study examined patients with stage III/IV ovarian cancer diagnosed between January 2000 and December 2013 identified using SEER-Medicare. Small or large bowel resection, ostomy creation, and upper abdominal procedures were identified using relevant billing codes and compared over time. A 1:1 primary and interval cytoreductive propensity matched cohort was created using demographic and clinical variables. 30-day complications and the use of acute care services were compared.
A total of 5417 women were identified. 34% underwent bowel resections, 16% ostomy creation, and 8% upper abdominal procedures. There was an increase in bowel resections and upper abdominal procedures from 2000 to 2013 in patients who underwent primary cytoreductive surgery. Compared with patients who received primary cytoreduction, patients who underwent interval cytoreductive surgery were less likely to undergo bowel resection (OR=0.50; 95% CI [0.41, 0.61]) or ostomy creation (OR=0.48; 95% CI [0.42, 0.56]). Upper abdominal procedures did not differ between groups. For patients who underwent primary cytoreductive surgery, these procedures were associated with intensive care unit stay (4.6% vs <2%, P<0.01). In both primary and interval cytoreductive surgery patients, the receipt of bowel and upper abdominal procedures was associated with multiple 30-day postoperative complications and higher rates of readmission and emergency room visits.
The performance of upper abdominal procedures in ovarian cancer patients increased from 2000 to 2013. Interval cytoreductive surgery was associated with decreased likelihood of bowel surgery. In matched primary and interval cytoreductive surgery cohorts, the receipt of these procedures were associated with the increased likelihood of postoperative complications and use of acute care services.
在美国,卵巢癌初始治疗方法的趋势反映了一种范式转变,即越来越多地采用新辅助化疗和间隔减瘤手术。本研究旨在评估接受初次或间隔减瘤手术的卵巢癌患者的手术减瘤程序趋势。
本回顾性基于人群的研究使用 SEER-Medicare 对 2000 年 1 月至 2013 年 12 月期间诊断为 III/IV 期卵巢癌的患者进行了研究。使用相关计费代码识别小肠或大肠切除术、造口术和上腹部手术,并随时间进行比较。使用人口统计学和临床变量创建了初次和间隔减瘤倾向匹配队列。比较了 30 天并发症和急性护理服务的使用情况。
共确定了 5417 名女性。34%的患者接受了肠切除术,16%的患者接受了造口术,8%的患者接受了上腹部手术。在接受初次细胞减灭术的患者中,2000 年至 2013 年肠切除术和上腹部手术的数量有所增加。与接受初次细胞减灭术的患者相比,接受间隔细胞减灭术的患者不太可能接受肠切除术(OR=0.50;95%CI [0.41, 0.61])或造口术(OR=0.48;95%CI [0.42, 0.56])。两组之间上腹部手术无差异。对于接受初次细胞减灭术的患者,这些手术与重症监护病房住院有关(4.6%与<2%,P<0.01)。在初次和间隔细胞减灭术患者中,接受肠和上腹部手术与多种 30 天术后并发症和更高的再入院率和急诊就诊率相关。
2000 年至 2013 年,卵巢癌患者上腹部手术的实施有所增加。间隔细胞减灭术与肠手术的可能性降低相关。在初次和间隔细胞减灭术的匹配队列中,接受这些手术与术后并发症和急性护理服务使用增加的可能性相关。